Skip to main content

Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers

Completed · Phase 1 · NCT03005782

Conditions: Malignancies

At a glance

Research payments reported, 2025
$392,128
U.S. investigators named
29
Sites paid
23
Planned or actual enrollment
333

About the trial

Sponsor
Regeneron Pharmaceuticals
Tested
REGN3767 (drug), cemiplimab (drug)
Dates
Started 2016-11-07; completion 2024-04-02
Results posted
Not yet

The primary objectives in the dose escalation phase are to evaluate safety and pharmacokinetics (PK) in order to determine the selected dose level(s) for expansion of REGN3767 as monotherapy and in combination with cemiplimab in patients with advanced malignancies, including lymphoma. The primary objectives in the dose expansion phase are to assess preliminary anti-tumor activity of REGN3767 alone and in combination with cemiplimab (separately by cohort) as measured by objective response rate (ORR).

From ClinicalTrials.gov, last updated 2024-05-01. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Regeneron Pharmaceuticals, Inc. reported $392,128 in research payments for this study in 2025 (45 payments).

Products named: Libtayo

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.